Suppr超能文献

阿奇霉素、阿莫西林/克拉维酸和头孢克洛治疗急性耳鼻喉感染的比较

[Comparison of azithromycin, amoxicillin/clavulanic acid and cefaclor in the treatment of acute ENT infections].

作者信息

García Callejo F J, Velert Vila M M, Orts Alborch M H, Pardo Mateu L, Esparcia Navarro M

机构信息

Servicio de ORL, Hospital Clínico Universitario, Valencia.

出版信息

Acta Otorrinolaringol Esp. 1998 May;49(4):306-12.

PMID:9707742
Abstract

A comparison was made of the clinical effectiveness of azithromycin (once daily for three days at a dose of 10 mg/kg in children or 500 mg/day in adults) and amoxicillin/clavulanic acid and cefaclor (standard doses for 7 to 14 days) in acute ear, nose and throat infections in an open randomized study. The group with azithromycin included 37 otitis media, 24 pharyngotonsillitis and 6 maxillary sinusitis (n = 67). The amoxicillin/clavulanic acid group, 22 otitis media, 19 pharyngotonsillitis and 6 maxillary sinusitis (n = 47) and the cefaclor group, 15 otitis media, 12 pharyngotonsillitis and 4 maxillary sinusitis (n = 31). Fifteen days after beginning treatment, 97% (65/67) of the patients who received azithromycin had improved or cured, compared with 85% (40/47) of those who received amoxicillin/clavulanic acid and 84% (26/31), cefaclor (p < 0.02). Pathogens were not eradicated in 3% (2/58) of the patients who received azithromycin, compared with 13% (4/28) who received amoxicillin/clavulanic acid and 15% (4/28) cefaclor. Patients with azithromycin showed an earlier clinical improvement and more rapid normalization of the leukocyte count, erythrocyte sedimentation rate and acute phase proteins. No patient with azithromycin had adverse effects, versus 15% (7/47) for patients with amoxicillin/clavulanic acid and 16% (5/31) for cefaclor. Treatment compliance was 100, 83 (39/47) and 84% (26/31), respectively (p < 0.01). We conclude that azithromycin treatment for three days is faster and more effective clinically and analytically than standard treatment with amoxicillin/clavulanic acid or cefaclor in acute infections of the ear, nose and throat.

摘要

在一项开放性随机研究中,对阿奇霉素(儿童剂量为10mg/kg,每日一次,共三天;成人剂量为500mg/天)、阿莫西林/克拉维酸和头孢克洛(标准剂量,疗程7至14天)治疗急性耳、鼻、喉感染的临床疗效进行了比较。阿奇霉素组包括37例中耳炎、24例咽扁桃体炎和6例上颌窦炎(n = 67)。阿莫西林/克拉维酸组包括22例中耳炎、19例咽扁桃体炎和6例上颌窦炎(n = 47),头孢克洛组包括15例中耳炎、12例咽扁桃体炎和4例上颌窦炎(n = 31)。治疗开始15天后,接受阿奇霉素治疗的患者中有97%(65/67)病情改善或治愈,接受阿莫西林/克拉维酸治疗的患者为85%(40/47),接受头孢克洛治疗的患者为84%(26/31)(p < 0.02)。接受阿奇霉素治疗的患者中3%(2/58)的病原体未被清除,接受阿莫西林/克拉维酸治疗的患者为13%(4/28),接受头孢克洛治疗的患者为15%(4/28)。接受阿奇霉素治疗的患者临床改善更早,白细胞计数、红细胞沉降率和急性期蛋白恢复正常的速度更快。接受阿奇霉素治疗的患者无不良反应,而接受阿莫西林/克拉维酸治疗的患者为15%(7/47),接受头孢克洛治疗的患者为16%(5/31)。治疗依从性分别为100%、83%(39/47)和84%(26/31)(p < 0.01)。我们得出结论,在急性耳、鼻、喉感染中,阿奇霉素治疗三天在临床和分析方面比阿莫西林/克拉维酸或头孢克洛的标准治疗更快、更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验